
Maxime Dougados

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8621841/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2023, 82, 763-772.	0.5	18
2	Response to: â€~Correspondence on â€~EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Fallon <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e174-e174.	0.5	14
3	Response to: â€~Comment on: â€~EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec <i>et al</i> ' by Wei <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e139-e139.	0.5	30
4	Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension. Rheumatology, 2022, 61, 617-627.	0.9	3
5	Root joint involvement in spondyloarthritis: a <i>post hoc</i> analysis from the international ASAS-PerSpA study. Rheumatology, 2022, 61, 667-678.	0.9	4
6	Metacarpophalangeal Joint Impairment in Hand Osteoarthritis and Its Association With Mechanical Factors: Results From the Digital Cohort Osteoarthritis Design Hand Osteoarthritis Cohort. Arthritis Care and Research, 2022, 74, 1696-1703.	1.5	3
7	Individual-level and country-level socio-economic factors and health outcomes in spondyloarthritis: analysis of the ASAS-perSpA study. Rheumatology, 2022, 61, 2043-2053.	0.9	5
8	Disease activity outcome measures are only available in half of the electronic medical files of patients with axial spondyloarthritis followed in an outpatient clinic: the results of an audit of a tertiary-care rheumatology department. Rheumatology International, 2022, 42, 825-829.	1.5	5
9	2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis. Joint Bone Spine, 2022, 89, 105344.	0.8	44
10	Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort. RMD Open, 2022, 8, e001846.	1.8	1
11	Evaluation of the prevalence of musculoskeletal conditions in consecutive patients with skin psoriasis: a descriptive cross-sectional study. Rheumatology International, 2022, , 1.	1.5	1
12	Systematic assessment of heart valves and cardiac function by echocardiography in axial spondyloarthritis: a systematic review and meta-analysis. Joint Bone Spine, 2022, , 105375.	0.8	2
13	Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France. RMD Open, 2022, 8, e002106.	1.8	4
14	Impact of a clinical pharmacist in a multidisciplinary consultation on the switch to a biosimilar for inflammatory rheumatic diseases. Joint Bone Spine, 2022, 89, 105322.	0.8	0
15	Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials. Rheumatology International, 2022, 42, 205-213.	1.5	0
16	The impact of psoriasis on the clinical characteristics, disease burden and treatment patterns of peripheral spondyloarthritis. Rheumatology, 2022, 62, 135-146.	0.9	1
17	Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis. Rheumatology International, 2022, 42, 1751-1766.	1.5	5
18	Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the FSPOIR cohort, RMD Open, 2022, 8, e002040.	1.8	0

#	Article	IF	CITATIONS
19	What is peripheral spondyloarthritis? Identifying proportion, phenotype and burden in post hoc analysis of the ASAS-PerSpA study. Seminars in Arthritis and Rheumatism, 2022, 55, 152012.	1.6	7
20	Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: <scp>Three‥ear</scp> Results From a Phase <scp>Ilb</scp> Randomized Controlled Trial and Its <scp>Open‣abel</scp> Extension Study. Arthritis and Rheumatology, 2022, 74, 1943-1958.	2.9	9
21	Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) Versus ASDAS: A Post Hoc Analysis of a Randomized Controlled Trial. Journal of Rheumatology, 2022, 49, 1100-1108.	1.0	5
22	Pregnancy rates and outcomes in early axial spondyloarthritis: An analysis of the DESIR cohort. Joint Bone Spine, 2021, 88, 105075.	0.8	7
23	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.5	158
24	Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. Joint Bone Spine, 2021, 88, 105071.	0.8	5
25	Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Annals of the Rheumatic Diseases, 2021, 80, 475-486.	0.5	17
26	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term studyÂ. Rheumatology, 2021, 60, 2256-2266.	0.9	12
27	Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology, 2021, 60, 3738-3746.	0.9	24
28	Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA). Rheumatology, 2021, 60, 888-895.	0.9	21
29	Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis. Advances in Therapy, 2021, 38, 226-248.	1.3	6
30	Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center. European Journal of Clinical Pharmacology, 2021, 77, 25-33.	0.8	8
31	Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. Arthritis Research and Therapy, 2021, 23, 43.	1.6	12
32	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open, 2021, 7, e001450.	1.8	64
33	Does smoking affect level of seropositivity in RA? A post-HOC global and inter-country analysis of COMORA cohort. Rheumatology International, 2021, 41, 699-705.	1.5	4
34	Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Annals of the Rheumatic Diseases, 2021, 80, 1436-1444.	0.5	58
35	The adherence questionnaires in chronic inflammatory rheumatic diseases and their psychometric properties: A systematic literature review. Joint Bone Spine, 2021, 88, 105160.	0.8	0
36	Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology, 2021, 60, 5073-5079.	0.9	12

#	Article	IF	CITATIONS
37	Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic. Lancet Rheumatology, The, 2021, 3, e395-e396.	2.2	7
38	Association between individual and country-level socioeconomic factors and work participation in spondyloarthritis including psoriatic arthritis: Analysis of the ASAS-perSpA study. Seminars in Arthritis and Rheumatism, 2021, 51, 804-812.	1.6	5
39	Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey. Journal of Rheumatology, 2021, 48, 1810-1814.	1.0	3
40	Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open, 2021, 7, e001752.	1.8	11
41	How to fill the gap between clinical trials and daily practice in chronic inflammatory rheumatic diseases?. Joint Bone Spine, 2021, 88, 105252.	0.8	Ο
42	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. RMD Open, 2021, 7, e001728.	1.8	5
43	Impact of a pharmacist-led programme on biologics knowledge and adherence in patients with spondyloarthritis. Clinical and Experimental Rheumatology, 2021, 39, 811-818.	0.4	2
44	Adherence to and patient's knowledge of self-management of subcutaneous biologic therapy in chronic inflammatory rheumatic diseases: results of a multicentre cross-sectional study. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
45	Elucidating the role of a positive family history in differentiating between axial and peripheral spondyloarthritis: an ancillary analysis of the ASAS-PerSpA study Clinical and Experimental Rheumatology, 2021, , .	0.4	0
46	Response to †Everything we see is a perspective, not the truth' by Chattopadhyay <i>et al</i> . Annals of the Rheumatic Diseases, 2020, 79, e46-e46.	0.5	2
47	Effect of Gut Involvement in Patients with High Probability of Early Spondyloarthritis: Data from the DESIR Cohort. Journal of Rheumatology, 2020, 47, 349-353.	1.0	9
48	Peripheral Manifestations in Spondyloarthritis and their Effect: An Ancillary Analysis of the ASAS-COMOSPA Study. Journal of Rheumatology, 2020, 47, 211-217.	1.0	24
49	Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2020, 47, 6-14.	1.0	3
50	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. Journal of Rheumatology, 2020, 47, 809-819.	1.0	16
51	2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases, 2020, 79, 39-52.	0.5	506
52	Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study. Health and Quality of Life Outcomes, 2020, 18, 4.	1.0	10
53	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Annals of the Rheumatic Diseases, 2020, 79, 176-185.	0.5	76
54	Which imaging outcomes for axSpA are most sensitive to change? A 5‥ear analysis of The DESIR Cohort. Arthritis Care and Research, 2020, , .	1.5	5

#	Article	IF	CITATIONS
55	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. RMD Open, 2020, 6, e001211.	1.8	17
56	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1290-1297.	0.5	61
57	Inflammation of the sacroiliac joints and spine on MRI predicts structural changes on MRI in axial spondyloarthritis: 5â€year data from DESIR. Arthritis Care and Research, 2020, , .	1.5	4
58	Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. Rheumatology and Therapy, 2020, 7, 759-774.	1.1	6
59	5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort. RMD Open, 2020, 6, e001093.	1.8	10
60	Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. Rheumatology and Therapy, 2020, 7, 581-599.	1.1	13
61	Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial. Seminars in Arthritis and Rheumatism, 2020, 50, 701-708.	1.6	11
62	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 760-770.	0.5	205
63	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases, 2020, 79, 453-459.	0.5	43
64	Integrated longitudinal analysis does not compromise precision and reduces bias in the study of imaging outcomes: A comparative 5-year analysis in the DESIR cohort. Seminars in Arthritis and Rheumatism, 2020, 50, 1394-1399.	1.6	5
65	Agreement with the French 2019 recommendations on treatment adherence in rheumatic diseases among 357 health professionals. Joint Bone Spine, 2020, 87, 513-515.	0.8	0
66	Treat to target in axial spondyloarthritis: From its concept to its implementation. Journal of Autoimmunity, 2020, 110, 102398.	3.0	25
67	Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR. Joint Bone Spine, 2020, 87, 497-499.	0.8	4
68	Patient global assessment and radiographic progression in early arthritis: 3â€year results from the ESPOIR cohort. Arthritis Care and Research, 2020, 73, 1300-1305.	1.5	9
69	What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. Annals of the Rheumatic Diseases, 2020, 79, 324-331.	0.5	41
70	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.5	1,860
71	Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases, 2020, 79, 595-604.	0.5	91
72	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2020, 79, 193-201.	0.5	59

#	Article	IF	CITATIONS
73	Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. Seminars in Arthritis and Rheumatism, 2020, 50, 1449-1456.	1.6	29
74	Data to be collected for an optimal management of axial spondyloarthritis in daily practice: Proposal from evidence-based and consensual approaches. Joint Bone Spine, 2020, 87, 405-411.	0.8	13
75	Referring early arthritis patients within 6 weeks versus 12 weeks after symptom onset: an observational cohort study. Lancet Rheumatology, The, 2020, 2, e332-e338.	2.2	9
76	Clinical manifestations, disease activity and disease burden of radiographic versus non-radiographic axial spondyloarthritis over 5 years of follow-up in the DESIR cohort. Annals of the Rheumatic Diseases, 2020, 79, 209-216.	0.5	21
77	Safety of surgery in patients with rheumatoid arthritis treated with tocilizumab: data from the French (REGistry -RoAcTEmra) Regate registry. Clinical and Experimental Rheumatology, 2020, 38, 405-410.	0.4	5
78	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. Annals of the Rheumatic Diseases, 2019, 78, 1545-1549.	0.5	71
79	Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. RMD Open, 2019, 5, e000914.	1.8	7
80	Impact des comorbidités sur la fatigue dans la polyarthrite rhumatoÃ⁻deÂ: Résultats d'un programme infirmier de prise en charge des comorbidités (COMEDRA). Revue Du Rhumatisme (Edition Francaise), 2019, 86, 597-603.	0.0	0
81	Could a methotrexate blood assay improve adherence?. Nature Reviews Rheumatology, 2019, 15, 577-578.	3.5	Ο
82	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ: British Medical Journal, 2019, 364, l67.	2.4	76
83	Novel DMARD monotherapy in rheumatoid arthritis. Lancet, The, 2019, 393, 2277-2278.	6.3	4
84	Evaluation of concomitant peripheral arthritis in patients with recent onset axial spondyloarthritis: 5-year results from the DESIR cohort. Arthritis Research and Therapy, 2019, 21, 139.	1.6	19
85	Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain. Arthritis Research and Therapy, 2019, 21, 63.	1.6	1
86	Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. Rheumatology, 2019, 58, 1498-1499.	0.9	7
87	Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). Annals of the Rheumatic Diseases, 2019, 78, 486-493.	0.5	24
88	Assessment of the adherence to disease-modifying drugs in patients with chronic inflammatory rheumatic diseases: Results of a survey of 1594 patients. Joint Bone Spine, 2019, 86, 610-614.	0.8	8
89	Measuring spinal mobility in early axial spondyloarthritis: does it matter?. Rheumatology, 2019, 58, 1597-1606.	0.9	16
90	ls a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. Rheumatology, 2019, 58, 1649-1654.	0.9	23

#	Article	IF	CITATIONS
91	Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. Journal of Rheumatology, 2019, 46, 896-903.	1.0	14
92	Deregulation of microRNA expression in monocytes and CD4+ T lymphocytes from patients with axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 51.	1.6	21
93	SAT0337â€MORE THAN 30% PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS PRESENT WITH PERIPHERAL ARTHRITIS: INCIDENCE AND FACTORS ASSOCIATED DURING 5 YEARS OF FOLLOW-UP OF THE DESIR COHORT. , 2019, , .		0
94	FRI0373â€5-YEARS TREATMENT EFFECT OF TNF ALPHA INHIBITOR IN EARLY AXIAL SPONDYLOARTHRITIS AND ASSOCIATED FACTORS: AN INVERSE PROBABILITY WEIGHTING ANALYSIS OF THE DESIR COHORT. , 2019, , .		0
95	OP0012â€EFFECTIVENESS OF TNFI AFTER A FIRST SWITCH IS LOWER IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS: A LONGITUDINAL ANALYSIS OF THE DESIR COHORT. , 2019, , .		0
96	THU0391â€COMPARISON OF CHARACTERISTICS AND BURDEN OF DISEASE IN PATIENTS WITH RADIOGRAPHIC AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS. , 2019, , .		0
97	OP0227â€EFFECTS OF SUCCESSIVE SWITCHES TO DIFFERENT BIOSIMILARS INFLIXIMAB ON IMMUNOGENICITY CHRONIC INFLAMMATORY DISEASES IN DAILY CLINICAL PRACTICE. , 2019, , .	'IN	1
98	SAT0345â€PREGNANCY RATES AND OUTCOMES IN EARLY AXIAL SPONDYLOARTHRITIS: ANALYSIS OF THE DESI COHORT. , 2019, , .	R	0
99	OP0031â€ARE THE MODIFIED NEW YORK AND ASAS AXIAL SPONDYLOARTHRITIS CRITERIA INTERCHANGEABLE THE CLASSIFICATION OF SPONDYLOARTHRITIS PATIENTS WITH RADIOGRAPHIC SACROILIITIS: COMPARISON IN 8 COHORTS?. , 2019, , .	IN	0
100	Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open, 2019, 5, e001041.	1.8	104
101	Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open, 2019, 5, e001035.	1.8	113
102	Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open, 2019, 5, e001108.	1.8	77
103	Impact of comorbidities on fatigue in rheumatoid arthritis patients: Results from a nurse-led program for comorbidities management (COMEDRA). Joint Bone Spine, 2019, 86, 55-60.	0.8	27
104	ls active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts. Rheumatology, 2019, 58, 798-802.	0.9	11
105	Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis. Rheumatology International, 2019, 39, 141-146.	1.5	9
106	Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine, 2019, 86, 135-150.	0.8	90
107	Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five‥ear Results From the <scp>DESIR</scp> Cohort. Arthritis Care and Research, 2019, 71, 1678-1684.	1.5	38
108	Low incidence of vertebral fractures in early spondyloarthritis: 5-year prospective data of the DESIR cohort. Annals of the Rheumatic Diseases, 2019, 78, 60-65.	0.5	9

#	Article	IF	CITATIONS
109	Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. Joint Bone Spine, 2019, 86, 13-19.	0.8	39
110	Response to: â€~ "Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study―by Moltó et al: still a long way to go in the assessment of patients with spondyloarthritis and concomitant fibromyalgia?' by Altobelli et al. Annals of the Rheumatic Diseases, 2019, 78, e40-e40.	0.5	1
111	Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients. Clinical and Experimental Rheumatology, 2019, 37, 26-31.	0.4	11
112	Clinical peripheral enthesitis in the DESIR prospective longitudinal axial spondyloarthritis cohort. Clinical and Experimental Rheumatology, 2019, 37, 561-565.	0.4	4
113	Evaluation of the predictive validity of the ASAS axial spondyloarthritis criteria in the DESIR cohort. Clinical and Experimental Rheumatology, 2019, 37, 797-802.	0.4	3
114	Adherence to recommendations for the use of anti–tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. Rheumatology, 2018, 57, 880-890.	0.9	8
115	Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. Clinical Rheumatology, 2018, 37, 1503-1510.	1.0	13
116	2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. Joint Bone Spine, 2018, 85, 275-284.	0.8	80
117	The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study. Journal of Rheumatology, 2018, 45, 795-801.	1.0	17
118	Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study. Scientific Reports, 2018, 8, 5446.	1.6	56
119	MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations â€~Not everything that glisters is gold (standard)'. RMD Open, 2018, 4, e000586.	1.8	51
120	Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 221-227.	0.5	40
121	An e-health interactive self-assessment website (Sanoia \hat{A}^{\otimes}) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients. Joint Bone Spine, 2018, 85, 709-714.	0.8	51
122	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 476-479.	0.5	47
123	In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. Annals of the Rheumatic Diseases, 2018, 77, 470-472.	0.5	8
124	Classification criteria versus physician's opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis. Joint Bone Spine, 2018, 85, 85-91.	0.8	14
125	Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study. Annals of the Rheumatic Diseases, 2018, 77, 1091-1093.	0.5	16
126	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.5	484

#	Article	IF	CITATIONS
127	Development of a comorbidity self-questionnaire for patients with inflammatory joint disease. Joint Bone Spine, 2018, 85, 261-262.	0.8	4
128	An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Annals of the Rheumatic Diseases, 2018, 77, 124-127.	0.5	51
129	Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 78-84.	0.5	37
130	Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Seminars in Arthritis and Rheumatism, 2018, 47, 741-748.	1.6	63
131	Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Annals of the Rheumatic Diseases, 2018, 77, 533-540.	0.5	72
132	Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2018, 77, 405-411.	0.5	34
133	Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. Journal of Rheumatology, 2018, 45, 206-212.	1.0	31
134	Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. Joint Bone Spine, 2018, 85, 447-453.	0.8	21
135	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. RMD Open, 2018, 4, e000755.	1.8	15
136	226 Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate-inadequate responder patient population. Rheumatology, 2018, 57, .	0.9	0
137	233â€fDurability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. Rheumatology, 2018, 57, .	0.9	0
138	Comorbidities in spondyloarthritis including psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2018, 32, 390-400.	1.4	28
139	Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. RMD Open, 2018, 4, e000766.	1.8	16
140	219 Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities. Rheumatology, 2018, 57, .	0.9	1
141	Which scoring method depicts spinal radiographic damage in early axial spondyloarthritis best? Five-year results from the DESIR cohort. Rheumatology, 2018, 57, 1991-2000.	0.9	11
142	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet, The, 2018, 392, 2441-2451.	6.3	251
143	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Annals of the Rheumatic Diseases, 2018, 77, 1705-1709.	0.5	83
144	Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open, 2018, 4, e000662.	1.8	18

#	Article	IF	CITATIONS
145	Increase In Il-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis. Scientific Reports, 2018, 8, 7731.	1.6	17
146	Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review. RMD Open, 2018, 4, e000684.	1.8	37
147	Can power Doppler ultrasound of the entheses help in classifying recent axial spondyloarthritis? Data from the DESIRÂcohort. RMD Open, 2018, 4, e000686.	1.8	9
148	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 1311-1317.	0.5	85
149	Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2018, 77, 1303-1310.	0.5	18
150	Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international study. Clinical and Experimental Rheumatology, 2018, 36, 210-214.	0.4	8
151	A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2018, 36, 1056-1060.	0.4	16
152	Evaluation of extreme patient-reported outcome in early spondyloarthritis and its impact on the effect of TNF- \hat{l}_{\pm} blockers treatment. Clinical and Experimental Rheumatology, 2018, 36, 1043-1048.	0.4	1
153	Use of nonsteroidal anti-inflammatory drugs in early axial spondyloarthritis in daily practice: Data from the DESIR cohort. Joint Bone Spine, 2017, 84, 79-82.	0.8	9
154	Patient and physician agreement on reported Bath Ankylosing Spondylitis Disease Activity Index in patients with axial spondyloarthritis. Joint Bone Spine, 2017, 84, 749-750.	0.8	3
155	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. Rheumatology, 2017, 56, kew476.	0.9	10
156	Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Annals of the Rheumatic Diseases, 2017, 76, 1797-1802.	0.5	52
157	2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases, 2017, 76, 948-959.	0.5	393
158	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1113-1136.	0.5	195
159	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 978-991.	0.5	1,220
160	Can we use structural lesions seen on MRI of the sacroiliac joints reliably for the classification of patients according to the ASAS axial spondyloarthritis criteria? Data from the DESIR cohort. Annals of the Rheumatic Diseases, 2017, 76, 392-398.	0.5	45
161	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.5	3,366
162	Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort. Annals of the Rheumatic Diseases, 2017, 76, 1036-1041.	0.5	25

#	Article	IF	CITATIONS
163	Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients. Rheumatology, 2017, 56, kew456.	0.9	1
164	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology, 2017, 56, 1498-1509.	0.9	78
165	Effects of Longâ€Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104â€Week Results From a Randomized, Placeboâ€Controlled Study. Arthritis Care and Research, 2017, 69, 1590-1598.	1.5	28
166	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology, 2017, 56, 1573-1578.	0.9	71
167	Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open, 2017, 3, e000410.	1.8	28
168	Tracking JAKs in spondyloarthritis: rationale and expectations. Annals of the Rheumatic Diseases, 2017, 76, 1325-1326.	0.5	5
169	Fibromyalgia and central sensitization in chronic inflammatory joint diseases. Joint Bone Spine, 2017, 84, 511-513.	0.8	18
170	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1101-1136.	0.5	277
171	Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Crossâ€6ectional Study of 977 Patients. Arthritis Care and Research, 2017, 69, 1504-1509.	1.5	25
172	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases, 2017, 76, 88-95.	0.5	295
173	Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open, 2017, 3, e000448.	1.8	16
174	Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. Annals of the Rheumatic Diseases, 2017, 76, 2054-2060.	0.5	21
175	Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology, 2017, 56, 1746-1754.	0.9	49
176	Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Annals of the Rheumatic Diseases, 2017, 76, 1823-1828.	0.5	130
177	The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study. Arthritis Research and Therapy, 2017, 19, 96.	1.6	16
178	MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation. Arthritis Research and Therapy, 2017, 19, 126.	1.6	46
179	Assessment of typical SpA lesions on MRI of the spine: do local readers and central readers agree in the DESIR-cohort at baseline?. Clinical Rheumatology, 2017, 36, 1551-1559.	1.0	9
180	Diagnostic delay in axial spondyloarthritis: A cross-sectional study of 432Âpatients. Joint Bone Spine, 2017, 84, 467-471.	0.8	49

#	Article	IF	CITATIONS
181	Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the â€~ORA' registry. RMD Open, 2017, 3, e000515.	1.8	14
182	Evaluation of Vitamin D Status in Rheumatoid Arthritis and Its Association with Disease Activity across 15 Countries: "The COMORA Study― International Journal of Rheumatology, 2017, 2017, 1-8.	0.9	38
183	Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures. BMC Musculoskeletal Disorders, 2017, 18, 357.	0.8	20
184	Large country differences in work outcomes in patients with RA – an analysis in the multinational study COMORA. Arthritis Research and Therapy, 2017, 19, 216.	1.6	20
185	Flare in axial spondyloarthritis: investigation of meaningful changes in symptomatic outcome measures. Clinical and Experimental Rheumatology, 2017, 35, 209-213.	0.4	6
186	Evaluation of whether extremely high enthesitis or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores suggest fibromyalgia and confound the anti-TNF response in early non-radiographic axial spondyloarthritis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 105, 50-53.	0.4	7
187	Psychometric properties of sleep and coping numeric rating scales in rheumatoid arthritis: a subanalysis of an etanercept trial. Clinical and Experimental Rheumatology, 2017, 35, 786-790.	0.4	5
188	Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatology, 2016, 55, kev340.	0.9	66
189	Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0146991.	1.1	52
190	Comorbidities in rheumatoid arthritis. Current Opinion in Rheumatology, 2016, 28, 282-288.	2.0	91
191	Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. Joint Bone Spine, 2016, 83, 501-509.	0.8	39
192	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. RMD Open, 2016, 2, e000323.	1.8	13
193	Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis. RMD Open, 2016, 2, e000205.	1.8	15
194	Reliability of mSASSS scoring in everyday practice in DESIR-cohort study centres: cross-sectional study of agreement with trained readers. Annals of the Rheumatic Diseases, 2016, 75, 2213-2214.	0.5	6
195	Costs of early spondyloarthritis: estimates from the first 3â€years of the DESIR cohort. RMD Open, 2016, 2, e000230.	1.8	14
196	Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis. RMD Open, 2016, 2, e000235.	1.8	14
197	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 294.	1.6	27
198	Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. Journal of Rheumatology, 2016, 43, 1285-1291.	1.0	26

#	Article	IF	CITATIONS
199	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2016, 43, 1680-1686.	1.0	42
200	What is the reliability of non-trained investigators in recognising structural MRI lesions of sacroiliac joints in patients with recent inflammatory back pain? Results of the DESIR cohort. RMD Open, 2016, 2, e000303.	1.8	14
201	Rheumatology training experience across Europe: analysis of core competences. Arthritis Research and Therapy, 2016, 18, 213.	1.6	19
202	Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. Journal of Rheumatology, 2016, 43, 1547-1552.	1.0	56
203	Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis. Arthritis Research and Therapy, 2016, 18, 42.	1.6	57
204	Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Annals of the Rheumatic Diseases, 2016, 75, 540-546.	0.5	67
205	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases, 2016, 75, 16-22.	0.5	275
206	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.5	1,114
207	Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort. Rheumatology, 2016, 55, 335-342.	0.9	23
208	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2016, 75, 1958-1963.	0.5	383
209	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Annals of the Rheumatic Diseases, 2016, 75, 1034-1042.	0.5	53
210	Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. Rheumatology, 2016, 55, 874-882.	0.9	49
211	Preliminary definitions of â€~flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Annals of the Rheumatic Diseases, 2016, 75, 991-996.	0.5	48
212	In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study. Rheumatology, 2016, 55, 735-744.	0.9	26
213	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 2016, 75, 490-498.	0.5	98
214	Evaluation of physiotherapy in a prospective cohort of early axial spondyloarthritis. Data from the DESIR cohort. Joint Bone Spine, 2016, 83, 185-190.	0.8	10
215	Fatigue in early axial spondyloarthritis. Results from the French DESIR cohort. Joint Bone Spine, 2016, 83, 427-431.	0.8	19
216	Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studies. Joint Bone Spine, 2016, 83, 101-103.	0.8	5

#	Article	IF	CITATIONS
217	Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Annals of the Rheumatic Diseases, 2016, 75, 1328-1335.	0.5	81
218	In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. Annals of the Rheumatic Diseases, 2016, 75, 715-720.	0.5	41
219	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2016, 75, 1016-1023.	0.5	188
220	Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Annals of the Rheumatic Diseases, 2016, 75, 874-878.	0.5	49
221	Response to: â€~Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases'. Screening for comorbidities: what is the remit of rheumatologists?. Annals of the Rheumatic Diseases, 2016, 75, e56-e56.	0.5	0
222	Prevalence and clinical characteristics of psoriasis in spondyloarthritis: a descriptive analysis of 275 patients. Clinical and Experimental Rheumatology, 2016, 34, 82-7.	0.4	2
223	Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. Clinical and Experimental Rheumatology, 2016, 34, 214-21.	0.4	10
224	Vitamin D, disease activity and comorbidities in early spondyloarthritis. Clinical and Experimental Rheumatology, 2016, 34, 396-403.	0.4	5
225	Prevalence of vitamin D deficiency in rheumatoid arthritis and association with disease activity and cardiovascular risk factors: data from the COMEDRA study. Clinical and Experimental Rheumatology, 2016, 34, 984-990.	0.4	9
226	Axial spondyloarthritis. Nature Reviews Disease Primers, 2015, 1, 15013.	18.1	135
227	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open, 2015, 1, e000153.	1.8	85
228	Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open, 2015, 1, e000019-e000019.	1.8	90
229	Development of Multinational Definitions of Minimal Clinically Important Improvement and Patient Acceptable Symptomatic State in Osteoarthritis. Arthritis Care and Research, 2015, 67, 972-980.	1.5	82
230	Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve‥ear Data. Arthritis Care and Research, 2015, 67, 1571-1577.	1.5	16
231	Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study. Journal of Rheumatology, 2015, 42, 1099-1104.	1.0	39
232	Impact of repeated measures of joint space width on the sample size calculation: An application to hip osteoarthritis. Joint Bone Spine, 2015, 82, 172-176.	0.8	5
233	Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort. Vaccine, 2015, 33, 1446-1452.	1.7	96
234	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Annals of the Rheumatic Diseases, 2015, 74, 8-13.	0.5	223

#	Article	IF	CITATIONS
235	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. RMD Open, 2015, 1, e000128.	1.8	17
236	Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology, 2015, 54, 633-640.	0.9	57
237	The burden of non-radiographic axial spondyloarthritis. Seminars in Arthritis and Rheumatism, 2015, 44, 556-562.	1.6	112
238	Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. International Journal of Cardiology, 2015, 183, 149-154.	0.8	17
239	Differences and similarities in rheumatology specialty training programmes across European countries. Annals of the Rheumatic Diseases, 2015, 74, 1183-1187.	0.5	18
240	Raising the quality of rheumatology management recommendations: lessons from the EULAR process 10 years after provision of standard operating procedures. Rheumatology, 2015, 54, 1392-1396.	0.9	5
241	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. Joint Bone Spine, 2015, 82, 345-351.	0.8	92
242	Classification of axial SpA based on positive imaging (radiographs and/or MRI of the sacroiliac joints) by local rheumatologists or radiologists versus central trained readers in the DESIR cohort. Annals of the Rheumatic Diseases, 2015, 74, 2016-2021.	0.5	65
243	Clinical and radiographic outcomes at 2â€years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Annals of the Rheumatic Diseases, 2015, 74, 35-43.	0.5	94
244	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Annals of the Rheumatic Diseases, 2015, 74, 1725-1733.	0.5	130
245	Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis. Journal of Rheumatology, 2015, 42, 1835-1841.	1.0	26
246	Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. Journal of Rheumatology, 2015, 42, 1962-1970.	1.0	116
247	Spondyloarthritis: A concept or a disease?. Joint Bone Spine, 2015, 82, 387-389.	0.8	38
248	Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis. Journal of Rheumatology, 2015, 42, 2361-2368.	1.0	3
249	Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175Âpatients. Joint Bone Spine, 2015, 82, 451-454.	0.8	9
250	Evaluation of Serum Interleukinâ€6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort. Arthritis Care and Research, 2015, 67, 905-912.	1.5	55
251	Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. Annals of the Rheumatic Diseases, 2015, 74, 1145-1149.	0.5	68
252	Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. Annals of the Rheumatic Diseases, 2015, 74, 746-751.	0.5	60

#	Article	IF	CITATIONS
253	Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Annals of the Rheumatic Diseases, 2015, 74, 52-59.	0.5	174
254	Dr. Hmamouchi, et al reply. Journal of Rheumatology, 2014, 41, 2492.1-2492.	1.0	0
255	Assessing structural changes in axial spondyloarthritis using a low-dose biplanar imaging system. Rheumatology, 2014, 53, 1669-1675.	0.9	11
256	Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Research and Therapy, 2014, 16, 481.	1.6	27
257	Early Increase of Abdominal Adiposity in Patients with Spondyloarthritis Receiving Anti-tumor Necrosis Factor-α Treatment. Journal of Rheumatology, 2014, 41, 1112-1117.	1.0	29
258	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1755-1760.	0.5	11
259	Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine, 2014, 81, 352-359.	0.8	39
260	Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine, 2014, 81, 6-14.	0.8	85
261	Rapidly destructive tibiofemoral knee osteoarthritis: Clinicoradiological presentation and outcome after global medical treatment including non-arthroscopic joint lavage plus corticosteroid injection. A single center retrolective study. Joint Bone Spine, 2014, 81, 142-148.	0.8	6
262	Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. Journal of Rheumatology, 2014, 41, 2395-2402.	1.0	63
263	Effectiveness of Tumor Necrosis Factor $\hat{I}\pm$ Blockers in Early Axial Spondyloarthritis: Data From the DESIR Cohort. Arthritis and Rheumatology, 2014, 66, 1734-1744.	2.9	32
264	Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Annals of the Rheumatic Diseases, 2014, 73, 1508-1514.	0.5	76
265	Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2014, 66, 2091-2102.	2.9	185
266	Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Annals of the Rheumatic Diseases, 2014, 73, 803-809.	0.5	123
267	Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Annals of the Rheumatic Diseases, 2014, 73, 1455-1461.	0.5	263
268	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases, 2014, 73, 62-68.	0.5	659
269	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2014, 73, 6-16.	0.5	397
270	The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis. Joint Bone Spine, 2014, 81, 154-159.	0.8	14

#	Article	IF	CITATIONS
271	Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Annals of the Rheumatic Diseases, 2013, 72, 815-822.	0.5	449
272	Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology, 2013, 52, 391-399.	0.9	39
273	Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Annals of the Rheumatic Diseases, 2013, 72, 43-50.	0.5	259
274	Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. Journal of Rheumatology, 2013, 40, 1650-1657.	1.0	38
275	Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology, 2012, 51, 1687-1696.	0.9	24
276	Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology, 2012, 51, 1894-1905.	0.9	32
277	Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 1623-1629.	0.5	223
278	Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Research and Therapy, 2012, 14, R129.	1.6	61
279	Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: Example of etanercept in advanced ankylosing spondylitis. Arthritis Care and Research, 2012, 64, 290-294.	1.5	15
280	Onset of action of etanercept in rheumatoid arthritis based on patient-reported outcomes. Clinical and Experimental Rheumatology, 2012, 30, 266-8.	0.4	4
281	Prevalence and characteristics of hip involvement in spondyloarthritis: a single-centre observational study of 275 patients. Clinical and Experimental Rheumatology, 2012, 30, 481-6.	0.4	13
282	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Annals of the Rheumatic Diseases, 2011, 70, 404-413.	0.5	657
283	Spondyloarthritis. Lancet, The, 2011, 377, 2127-2137.	6.3	648
284	The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine, 2011, 78, 598-603.	0.8	204
285	The Influence of the Definition of Patient Global Assessment in Assessment of Disease Activity According to the Disease Activity Score (DAS28) in Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2326-2328.	1.0	17
286	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 249-251.	0.5	208
287	Status versus changes, onset of action, and sustainabilityhow do we define and present these concepts in clinical trial reports in rheumatology?. Bulletin of the NYU Hospital for Joint Diseases, 2011, 69, 111-5.	0.7	0
288	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781

#	Article	IF	CITATIONS
289	A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Annals of the Rheumatic Diseases, 2010, 69, 1430-1435.	0.5	93
290	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Annals of the Rheumatic Diseases, 2010, 69, 638-643.	0.5	203
291	Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 828-833.	0.5	142
292	Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2010, 69, 631-637.	0.5	1,711
293	OARSI/OMERACT Criteria of Being Considered a Candidate for Total Joint Replacement in Knee/Hip Osteoarthritis as an Endpoint in Clinical Trials Evaluating Potential Disease Modifying Osteoarthritic Drugs. Journal of Rheumatology, 2009, 36, 2097-2099.	1.0	32
294	Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. Arthritis Research and Therapy, 2007, 9, R11.	1.6	47
295	Rituximab in Rheumatoid Arthritis. BioDrugs, 2007, 21, 342.	2.2	0
296	Practice patterns in outpatient rheumatology: A pilot evaluation of medical file content. Joint Bone Spine, 2007, 74, 171-174.	0.8	9
297	The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Joint Bone Spine, 2007, 74, 440-445.	0.8	161
298	Why and How to Use NSAIDs in Osteoarthritis. Journal of Cardiovascular Pharmacology, 2006, 47, S49-S54.	0.8	17
299	Symptomatic slow-acting drugs forÂosteoarthritis: what are theÂfacts?. Joint Bone Spine, 2006, 73, 606-609.	0.8	36
300	Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis and Rheumatism, 2005, 52, 1756-1765.	6.7	623
301	How can one develop disease-modifying drugs in osteoarthritis?. Current Rheumatology Reports, 2005, 7, 22-28.	2.1	3
302	Ankylosing spondylitis: how should the disease be assessed?. Best Practice and Research in Clinical Rheumatology, 2002, 16, 605-618.	1.4	14
303	Why is the concept of spondyloarthropathies important?. Best Practice and Research in Clinical Rheumatology, 2002, 16, 495-505.	1.4	9
304	Diacerein as a disease-modulating agent in osteoarthritis. Current Rheumatology Reports, 2001, 3, 479-483.	2.1	13
305	Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis and Rheumatism, 2001, 44, 180-185.	6.7	222
306	Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis and Rheumatism, 2001, 44, 1876-1886.	6.7	561

#	Article	IF	CITATIONS
307	Increased risk of ankylosing spondylitis among first-born children: Comment on the article by Baudoin et al. Arthritis and Rheumatism, 2001, 44, 1964-1964.	6.7	10
308	Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. Arthritis and Rheumatism, 2001, 45, 478-484.	6.7	57
309	The familial form of spondylarthropathy: A clinical study of 115 multiplex families. Arthritis and Rheumatism, 2000, 43, 1356-1365.	6.7	117
310	Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis. Arthritis and Rheumatism, 1999, 42, 2275-2280.	6.7	42
311	Association of a polymorphism in the collagen I ?1 gene with osteoporosis in French women. Arthritis and Rheumatism, 1998, 41, 187-188.	6.7	31
312	Hormonal modulation in systemic lupus erythematosus. Preliminary clinical and hormonal results with cyproterone acetate. Arthritis and Rheumatism, 1985, 28, 1243-1250.	6.7	65
313	Elucidating the role of a positive family history in differentiating between axial and peripheral spondyloarthritis: an ancillary analysis of the ASAS-PerSpA study. Clinical and Experimental Rheumatology, 0, , .	0.4	0
314	Adherence to and patient's knowledge of self-management of subcutaneous biologic therapy in chronic inflammatory rheumatic diseases: results of a multicentre cross-sectional study. Clinical and Experimental Rheumatology, 0, , .	0.4	0